18 studies found for:    asa404
Show Display Options
Rank Status Study
1 Completed Study of DMXAA (Now Known as ASA404) in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: DMXAA
2 Terminated Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor
Condition: Solid Tumors
Intervention: Drug: Vadimezan™
3 Terminated A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
Condition: Solid Tumor Malignancies
Intervention: Drug: ASA404, DMXAA, DXAA
4 Terminated An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
Conditions: Metastatic Cancer With Impaired Renal Function;   Metastatic Cancer With Normal Renal Function
Intervention: Drug: ASA404
5 Completed A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: ASA404
6 Terminated A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Condition: Metastatic Cancer
Intervention: Drug: ASA404, DMXAA or DXAA
7 Suspended Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Drug: Docetaxel;   Drug: ASA404
8 Terminated An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
Condition: Histologically-proven and Radiologically-confirmed Solid Tumors
Intervention: Drug: ASA404
9 Completed An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Intervention: Drug: ASA404
10 Completed Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
Condition: Advanced or Recurrent Solid Tumors
Intervention: Drug: vadimezan
11 Terminated A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404;   Drug: Placebo;   Drug: docetaxel
12 Withdrawn ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
Condition: Tumors
Interventions: Drug: ASA404;   Drug: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel
13 Completed Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: DMXAA in combination with carboplatin and paclitaxel
14 Terminated ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404;   Drug: Placebo;   Drug: carboplatin;   Drug: Paclitaxel
15 Completed Phase I Safety Study of DMXAA in Refractory Tumors
Condition: Refractory Tumors
Intervention: Drug: DMXAA
16 Completed Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: vadimezan
17 Completed Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: AS1404 (DMXAA)
18 Completed Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: vadimezan

Indicates status has not been verified in more than two years